Analysts Set Expectations for AnaptysBio, Inc.’s FY2017 Earnings (ANAB)

AnaptysBio, Inc. (NASDAQ:ANAB) – Equities researchers at Jefferies Group issued their FY2017 earnings estimates for shares of AnaptysBio in a research note issued to investors on Thursday. Jefferies Group analyst B. Amin anticipates that the biotechnology company will post earnings per share of ($1.65) for the year. Jefferies Group currently has a “Buy” rating and a $101.00 price objective on the stock. Jefferies Group also issued estimates for AnaptysBio’s Q4 2017 earnings at ($0.40) EPS, Q1 2018 earnings at ($0.24) EPS, Q2 2018 earnings at ($0.33) EPS, Q3 2018 earnings at ($0.37) EPS, Q4 2018 earnings at ($0.40) EPS, FY2018 earnings at ($1.33) EPS, FY2019 earnings at ($2.54) EPS, FY2020 earnings at ($3.27) EPS and FY2021 earnings at ($5.14) EPS.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.02.

COPYRIGHT VIOLATION NOTICE: “Analysts Set Expectations for AnaptysBio, Inc.’s FY2017 Earnings (ANAB)” was originally posted by Stock Observer and is the property of of Stock Observer. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.thestockobserver.com/2017/11/14/analysts-set-expectations-for-anaptysbio-inc-s-fy2017-earnings-anab.html.

Several other equities research analysts have also commented on the stock. Zacks Investment Research upgraded shares of AnaptysBio from a “sell” rating to a “hold” rating and set a $74.00 price target for the company in a report on Friday. Wedbush restated a “positive” rating and issued a $82.00 price target (up previously from $75.00) on shares of AnaptysBio in a report on Tuesday, November 7th. Stifel Nicolaus restated a “buy” rating and issued a $76.00 price target (up previously from $35.00) on shares of AnaptysBio in a report on Friday, October 13th. Robert W. Baird set a $69.00 price target on shares of AnaptysBio and gave the company a “buy” rating in a report on Wednesday, October 11th. Finally, Royal Bank Of Canada boosted their price target on shares of AnaptysBio from $40.00 to $79.00 and gave the company an “outperform” rating in a report on Tuesday, October 10th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $81.00.

Shares of AnaptysBio (NASDAQ ANAB) opened at $71.23 on Monday. AnaptysBio has a twelve month low of $15.17 and a twelve month high of $74.00. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.77 and a quick ratio of 10.77.

Institutional investors have recently modified their holdings of the company. Artal Group S.A. grew its position in shares of AnaptysBio by 459.4% in the 2nd quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock worth $5,983,000 after buying an additional 205,310 shares during the last quarter. Schwab Charles Investment Management Inc. grew its position in shares of AnaptysBio by 94.3% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 19,402 shares of the biotechnology company’s stock worth $465,000 after buying an additional 9,414 shares during the last quarter. Swiss National Bank purchased a new position in shares of AnaptysBio in the 2nd quarter worth approximately $242,000. State of New Jersey Common Pension Fund D purchased a new position in shares of AnaptysBio in the 3rd quarter worth approximately $1,922,000. Finally, Bank of New York Mellon Corp grew its position in shares of AnaptysBio by 46.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 19,744 shares of the biotechnology company’s stock worth $473,000 after buying an additional 6,297 shares during the last quarter. 59.04% of the stock is currently owned by hedge funds and other institutional investors.

In other news, major shareholder Holdings A/S Novo sold 356,300 shares of AnaptysBio stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $21.10, for a total value of $7,517,930.00. Following the transaction, the insider now owns 1,936,604 shares of the company’s stock, valued at approximately $40,862,344.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

About AnaptysBio

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Earnings History and Estimates for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply